AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Giacometti, A.
Right arrow Articles by Scalise, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Giacometti, A.
Right arrow Articles by Scalise, G.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2005, p. 1249-1252, Vol. 49, No. 3
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.3.1249-1252.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

In Vitro Activity of the Histatin Derivative P-113 against Multidrug-Resistant Pathogens Responsible for Pneumonia in Immunocompromised Patients

Andrea Giacometti,1* Oscar Cirioni,1 Wojciech Kamysz,2 Giuseppina D'Amato,1 Carmela Silvestri,1 Maria Simona Del Prete,1 Alberto Licci,1 Alessandra Riva,1 Jerzy Lukasiak,2 and Giorgio Scalise1

Institute of Infectious Diseases and Public Health, Università Politecnica delle Marche, Ancona, Italy,1 Faculty of Pharmacy, Medical University of Gdansk, Gdansk, Poland2

Received 21 July 2004/ Returned for modification 27 April 2004/ Accepted 15 November 2004

The in vitro activity of the histatin derivative P-113, alone or combined with eight antibiotics, was investigated against multidrug-resistant strains isolated from clinical specimens of immunocompromised patients with pneumonia. The gram-negative isolates were susceptible to P-113. S. aureus showed less susceptibility. Synergy was demonstrated when P-113 was combined with beta-lactams against gram-negative organisms.


* Corresponding author. Mailing address: Clinica Malattie Infettive, c/o Ospedale Regionale, via Conca 71, I-60020 Ancona, Italy. Phone: 39-071-5963467. Fax: 39-071-5963468. E-mail: anconacmi{at}interfree.it or a.giacometti{at}univpm.it.


Antimicrobial Agents and Chemotherapy, March 2005, p. 1249-1252, Vol. 49, No. 3
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.3.1249-1252.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2005 by the American Society for Microbiology. All rights reserved.